Upload
ritamaria
View
395
Download
0
Tags:
Embed Size (px)
Citation preview
Disseminated Intravascular CoagulationRobert R. Zaid D.O.
Genesys Regional Medical Center
PGY-I
Barcelona - Gaudi
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Primarily a thrombotic process– Systemic process producing both
thrombosis and hemorrhage– Also called consumption
coagulopathy and defibrination syndrome1
– Its clinical manifestation may be widespread hemorrhage in acute, fulminant cases2.
1. Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY2. Uptodote, 2005, www.utdol.com, Clinical feadures, diagnosis and teratment of disseminated intravascular coagulation
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology-Clinical Manifestations-Diagnosis-Treatment-Xigris
• Basic pathophysiology – Entry into the circulation of procoagulant
substances • Trigger systemic activation of the coagulation
system and platelets • Lead to the disseminated deposition of fibrin-
platelet thrombi.
– Procoagulant stimulus is tissue factor (most cases)
• Lipoprotein • Not normally exposed to blood.
– Tissue factor gains access to blood by • Tissue injury, • Malignant cells, • Expression on the surfaces of monocytes and
endothelial cells by inflammatory mediators.
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol. 1989;14:813–836.
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Tissue factor triggers – Thrombin
• Protease • Induces fibrin formation and platelet
activation
• Other procoagulants– Cysteine protease– Mucin– Trypsin
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Acute DIC– Coagulation factors are consumed at
a rate in excess of the capacity of the liver to synthesize them,
– Platelets are consumed in excess of the capacity of bone marrow megakaryocytes to release them.
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology-Clinical Manifestations-Diagnosis-Treatment-Xigris
• Laboratory manifestations– Prolonged prothrombin time (PT) – Prolonged Activated partial thromboplastin time
(aPTT) – Thrombocytopenia. – Increased fibrin formation
• Stimulates compensatory process of secondary fibrinolysis,
• Plasminogen activators generate plasmin to digest fibrin (and fibrinogen) into fibrin(ogen) degradation products (FDPs).
– FDPs are potent circulating anticoagulants that contribute further to the bleeding manifestations of DIC.
• Intravascular fibrin deposition can cause fragmentation of red blood cells and lead to the appearance of schistocytes in blood smears
• Hemolytic anemia is unusual in DIC. • Microvascular thrombosis in DIC can compromise
the blood supply to some organs and lead to multiorgan failure
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
Citadel Park
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• DIC always has an underlying etiology– Must be identified and eliminated to
treat the coagulopathy successfully.– The development of DIC in many of
these disorders is associated with an unfavorable outcome1.
• Occurs in 1% of hospitalized patients2
• Mortality rate approaches 40-80%
1. Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY2. Uptodote, 2005, www.utdol.com, Clinical feadures, diagnosis and teratment of disseminated intravascular coagulation
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Causes– Infection
• Most common cause of DIC. • The syndrome particularly is associated
with gram-negative or gram-positive sepsis
• Can be triggered by a variety of other– Bacterial
– Fungal
– Viral
– Rickettsial, and protozoal microorganisms.
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Obstetrics– The placenta and uterine contents
are rich sources of• Tissue factor • Other procoagulants that normally are
excluded from the maternal circulation
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
La Familia
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology-Clinical Manifestations-Diagnosis-Treatment-Xigris
– Clinical manifestations of DIC may accompany obstetric complications, especially in the third trimester.
• These syndromes range from – Acute, fulminant, and often fatal DIC in
amniotic fluid embolism » Blood is exposed to large amounts
of tissue factor in a short period of time creating large amounts of thrombin
» Multiorgan failure– Chronic or subacute DIC with a retained
dead fetus. » Exposure to small amounts of tissue
factor
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
– Other obstetric problems associated with DIC include
• Abruptio placentae• Toxemia• Septic abortion.
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Disseminated Intravascular Coagulation
-Background-Pathophysiology-Etiology-Clinical Manifestations-Diagnosis-Treatment-Xigris
• Clinical manifestations – Determined by
• Nature• Intensity• Duration of the underlying stimulus.
– Chronicity• Low-grade DIC is often asymptomatic
– Diagnosed only by laboratory abnormalities. – Bleeding is most common clinical finding
» Generalized or widespread ecchymoses• Chronic disease
– Thrombotic complications » Trousseau's syndrome in cancer » Gangrene of the digits or extremities» Hemorrhagic necrosis of the skin » Purpura fulminans
– Enhanced by• Coexistence of liver disease
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Candy Factory
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Diagnosis of severe, acute (easy)– Prolongation of PT, aPTT and Thrombin
time• Due to consumption and inhibitiion of clotting
factors
– Thrombocytopenia– Fibrin degradatin products
• Increased due to secondary fibrinolysis– Measured by latex agglutination or D-dimer
assays.
– Schistocytes may be seen in the peripheral blood smear
• Neither sensitive nor specific for DIC.
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology-Clinical Manifestations-Diagnosis-Treatment-Xigris
• Chronic or compensated forms of DIC – Highly variable patterns of abnormalities in
"DIC screen" coagulation tests. – Increased FDPs and prolonged PT are
generally more sensitive measures than are abnormalities of the aPTT and platelet count.
– Overcompensated synthesis of consumed clotting factors and platelets in some chronic forms
• Cause shortening of the PT and aPTT and/or thrombocytosis
• Though, elevated levels of FDPs indicate secondary fibrinolysis in such cases.
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Street entertainers
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Treatment– Identify underlying cause and treat– All other therapies are temporizing
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Asymptomatic patients with self-limited DIC – Have only laboratory manifestations
of the coagulopathy– No treatment may be necessary.
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Actively bleeding or who are at high risk of bleeding, – Blood component treatments of choice
• Transfusions of platelets – Improve the thrombocytopenia
• Fresh-frozen plasma (FFP)– Replace all consumed coagulation factors and
correct the prolonged PT and aPTT.
• Large volumes of plasma in severe cases
– The theoretical concern that these blood products may "fuel the fire" and exacerbate the DIC has not been supported by clinical experience
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Special cases– Profound hypofibrinogenemia
• Additional transfusion of cryoprecipitate,• Plasma concentrate enriched in
fibrinogen
– Sepsis• Infusion of antithrombin III concentrate
may be considered as an adjunctive measure
Schafer, A., I., Cecil Textbook of Medicine, Saunders, 2004, chapter 179, HEMORRHAGIC DISORDERS: DISSEMINATED INTRAVASCULAR COAGULATION, LIVER FAILURE, AND VITAMIN K DEFICIENCY
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology-Clinical Manifestations-Diagnosis-Treatment-Xigris
• Pharmacologic inhibitors of coagulation and fibrinolysis – Heparin – Theoretical benefit
• It blocks thrombin and the secondary fibrinolysis.
• Might exacerbate the bleeding tendency – Usually reserved for – Forms manifested by
» Thrombosis » Acrocyanosis » Cancer» Vascular malformations» Retained dead fetus» Acute promyelocytic leukemia.
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Antifibrinolytic agents, – ε-aminocaproic acid and tranexamic
acid– Generally are contraindicated
• May precipitate thrombosis
– May be effective in decreasing life-threatening bleeding
Festivals
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• XIGRIS® (Lilly)Drotrecogin alfa (activated) – Recombinant form of human
Activated Protein C
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology-Clinical Manifestations-Diagnosis-Treatment-Xigris
• General Pharmacology • Activated Protein C
– Antithrombotic effect – Inhibits Factors Va and VIIIa.
• Indirect profibrinolytic activity through its ability to inhibit plasminogen activator inhibitor-1 (PAI-1)
• Limits generation of activated thrombin-activatable-fibrinolysis-inhibitor.
• In vitro data indicate that Activated Protein C may exert an anti-inflammatory effect by inhibiting human tumor necrosis factor production by monocytes
– Blocks leukocyte adhesion to selectins– Limits the thrombin-induced inflammatory
responses within the microvascular endothelium.
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Clinical study (PROWESS)– 1690 patients with severe sepsis – Entry criteria included a systemic
inflammatory response presumed due to infection and at least one associated acute organ dysfunction
– The study was terminated after a planned interim analysis due to significantly lower mortality in patients on Xigris than in patients on placebo• (210/850, 25% vs. 259/840, 31% p=0.005).
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• INDICATIONS AND USAGE – Xigris is indicated for the reduction
of mortality in adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high risk of death (APACHE II)
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• Contraindications– Active internal bleeding – Recent (within 3 months) hemorrhagic
stroke – Recent (within 2 months) intracranial or
intraspinal surgery, or severe head trauma – Trauma with an increased risk of life-
threatening bleeding – Presence of an epidural catheter – Intracranial neoplasm or mass lesion or
evidence of cerebral herniation
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology-Clinical Manifestations-Diagnosis-Treatment-Xigris
• Warnings– Concurrent therapeutic dosing of heparin to treat an active
thrombotic or embolic event – Platelet count <30,000 × 10 6 /L, even if the platelet count is
increased after transfusions – Prothrombin time-INR >3.0 – Recent (within 6 weeks) gastrointestinal bleeding – Recent administration (within 3 days) of thrombolytic therapy – Recent administration (within 7 days) of oral anticoagulants or
glycoprotein IIb/IIIa inhibitors – Recent administration (within 7 days) of aspirin >650 mg per
day or other platelet inhibitors – Recent (within 3 months) ischemic stroke – Intracranial arteriovenous malformation or aneurysm – Known bleeding diathesis – Chronic severe hepatic disease – Any other condition in which bleeding constitutes a significant
hazard or would be particularly difficult to manage because of its location .
Disseminated Intravascular Coagulation
-Background
-Pathophysiology
-Etiology
-Clinical Manifestations
-Diagnosis
-Treatment
-Xigris
• DOSAGE AND ADMINISTRATION – Xigris should be administered
intravenously at an infusion rate of 24 µg/kg/hr for a total duration of infusion of 96 hours.
Any questions?